Immuneering Statistics
Total Valuation
Immuneering has a market cap or net worth of $57.53 million. The enterprise value is -$261,200.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, after market close.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 29.65 million shares outstanding. The number of shares has increased by 8.98% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 29.65M |
| Shares Change (YoY) | +8.98% |
| Shares Change (QoQ) | +0.96% |
| Owned by Insiders (%) | 29.21% |
| Owned by Institutions (%) | 25.99% |
| Float | 19.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.83 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.39, with a Debt / Equity ratio of 0.07.
| Current Ratio | 9.39 |
| Quick Ratio | 8.81 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -61.81% and return on invested capital (ROIC) is -39.70%.
| Return on Equity (ROE) | -61.81% |
| Return on Assets (ROA) | -37.42% |
| Return on Capital (ROIC) | -39.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$824,507 |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.71% in the last 52 weeks. The beta is -0.40, so Immuneering's price volatility has been lower than the market average.
| Beta (5Y) | -0.40 |
| 52-Week Price Change | -67.71% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.53 |
| Relative Strength Index (RSI) | 44.76 |
| Average Volume (20 Days) | 1,771,521 |
Short Selling Information
The latest short interest is 1.52 million, so 5.12% of the outstanding shares have been sold short.
| Short Interest | 1.52M |
| Short Previous Month | 1.63M |
| Short % of Shares Out | 5.12% |
| Short % of Float | 7.95% |
| Short Ratio (days to cover) | 0.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -60.47M |
| Pretax Income | -56.07M |
| Net Income | -56.07M |
| EBITDA | -60.09M |
| EBIT | -60.47M |
| Earnings Per Share (EPS) | -$1.91 |
Full Income StatementBalance Sheet
The company has $59.73 million in cash and $4.31 million in debt, giving a net cash position of $55.42 million or $1.87 per share.
| Cash & Cash Equivalents | 59.73M |
| Total Debt | 4.31M |
| Net Cash | 55.42M |
| Net Cash Per Share | $1.87 |
| Equity (Book Value) | 66.31M |
| Book Value Per Share | 2.24 |
| Working Capital | 56.90M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.82 million and capital expenditures -$298,318, giving a free cash flow of -$51.12 million.
| Operating Cash Flow | -50.82M |
| Capital Expenditures | -298,318 |
| Free Cash Flow | -51.12M |
| FCF Per Share | -$1.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |